Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1991 Jun;82(6):716–723. doi: 10.1111/j.1349-7006.1991.tb01908.x

Interleukin‐2‐inducible Killer Activity and Its Regulation by Blood Monocytes from Autologous Lymphocytes of Lung Cancer Patients

Saburo Sone 1, Eiji Kunishige 1, Farid Fawzy 1, Hiroaki Yanagawa 1, Akihiko Nil 1, Ken‐ichi Maeda 1, Shinji Atagi 1, Yuji Heike 1, Yasuhiko Nishioka 1, Kazuhito Mizuno 1, Takeshi Ogura 1
PMCID: PMC5918506  PMID: 1649813

Abstract

The ability of blood lymphocytes of newly diagnosed lung cancer patients to respond to interleukin 2 (IL‐2) to become IL‐2‐activated killer (LAK) cells and its regulation by autologous monocytes were examined. LAK activity was measured by 31Cr release assay. The abilities of lymphocytes among blood mononuclear cells (MNC) of subjects of different ages without malignancies to generate LAK activity against NK‐cell resistant Daudi cells and lung adenocarcinoma (PC‐9) cells were very similar. The LAK activity of blood MNC of lung cancer patients was also nearly the same as that of blood MNC of control subjects. There was no significant difference in IL‐2‐inducible LAK activity between MNC of patients with small cell lung cancer (SCLC) and those of patients with non‐SCLC. Monocytes and lymphocytes were separated from blood MNC on a one‐step Percoll gradient. Monocytes of lung cancer patients were found to augment in vitro induction of LAK activity by IL‐2 of autologous blood lymphocytes. In contrast, endotoxin‐stimulated monocytes suppressed LAK induction of autologous lymphocytes of cancer patients. These findings suggest that administration of IL‐2 and LAK cells induced in vitro may be of benefit in the treatment of lung cancer.

Keywords: Interleukin 2, Lymphocyte, Monocyte, Lung cancer

Full Text

The Full Text of this article is available as a PDF (465.1 KB).

REFERENCES

  • 1. ) Grimm , E. A. , Mazumder , A. , Zhang , H. Z. and Rosenberg , S. A.Lymphokine‐activated killer cell phenomenon. Lysis of natural killer‐resistant fresh solid tumor cells by interleukin‐2 activated autologous human peripheral blood lymphocytes . J. Exp. Med. , 155 , 1823 – 1841 ( 1982. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. ) Fujita , J. , Saijo , N. , Sasaki , Y. , Futami , H. , Ishihara , J. , Takahashi , H. , Hoshi , A , and Hamburger , A , Detection of cytotoxicity of freshly obtained lymphocytes and of lymphocytes activated with recombinant interleukin II (rIL‐2) against lung cancer cell lines by human tumor clonogenic assay (HTCA) . Eur. J. Cancer Clin Oncol , 22 , 445 – 450 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Rosenberg , S. A. , Lotze , M. T. , Muul , L. M. , Chang , A. E. , Avis , F. P. , Leitman , S. , Linehan , W. M. , Robertson , C. N. , Lee , R. E. , Rubin , J. T. , Seipp , C. A. , Simpson , C. G. and White , D. E. Aprogress report of the treatment of 157 patients with advanced cancer using lymphokine‐activated killer cells and interleukin‐2 or high‐dose of interleukin 2 alone . N. Engl. J. Med. , 316 , 889 – 897 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) West , W. H , Tauer , K. W. , Yannelli , J. R. , Marshall , G. D. , Orr , D. W. , Thurman , G. B. and Oldham , R. K.Constant‐infusion recombinant interleukin‐2 in adoptive immunotherapy of advanced cancer . N. Engl. J. Med. , 316 , 898 – 905 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Itoh , K. , Tidlen , A. B. and Balch , C. M.Role of interleukin‐2 and a serum suppressive factor on the induction of activated killer cell cytotoxicity for human melanoma cells . Cancer Res. , 45 , 3173 – 3178 ( 1985. ). [PubMed] [Google Scholar]
  • 6. ) Shiiba , K. , Suzuki , R. , Kawakami , K. , Ohuchi , A. and Kumagai , K.Interleukin‐2‐activated killer cells: generation in collaboration with interferon and its suppression in cancer patients . Cancer Immunol. Immunother. , 21 , 119 – 128 ( 1986. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. ) Itoh , K. , Pellis , N. R. and Balch , C. M.Monocyte‐dependent, serum‐borne suppressor of induction of lym‐phokine‐activated killer cells in lymphocytes from melanoma patients . Cancer Immunol Immunother. , 29 , 57 – 62 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. ) Ochoa , A. , Gromo , G. , Barbara , B. J. , Sondel , P. M. and Bach , F. H.Long term growth of lymphokine‐activated killer (LAK) cells: roles of anti‐CD‐3, β‐IL‐l, interferon andβ . J. Biol. , 138 , 2728 – 2733 ( 1987. ). [PubMed] [Google Scholar]
  • 9. ) Owen‐Schaub , L. B. , Gutterman , J. U. and Grimm , E. A.Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor α and interleukin 2 in the generation of human lymphokine‐activated killer cell cytotoxicity . Cancer Res. , 48 , 788 – 792 ( 1988. ). [PubMed] [Google Scholar]
  • 10. ) Singh , S. M. , Sone , S. , Inamura , N. and Ogura , T.Up‐regulation by granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) of induction of lymphokine (IL‐2)‐activated killer (LAK) cells by human blood monocytes . Int. J. Cancer , 44 , 170 – 176 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Sone , S. , Utsugi , T. , Nii , A. and Ogura , T.Differential effects of recombinant interferon α, β, and on the induction of human lymphokine (IL‐2)‐activated killer activity . J. Natl. Cancer Inst. , 80 , 425 – 431 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Yang , S. S. , Malek , T. R. , Hargrove , M. E. and Ting , C. C.Lymphokine‐induced cytotoxicity: requirement of two lymphokines for the induction of optimal cytotoxic responses . J. Immunol. , 134 , 3912 – 3919 ( 1985. ). [PubMed] [Google Scholar]
  • 13. ) Nii , A. , Sone , S. , Utsugi , T. and Ogura , T.Up‐ and down‐regulation of human lymphokine (IL‐2)‐activated killer cell induction by monocytes depending on their functional state . Int. J. Cancer , 41 , 33 – 40 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Sone , S. , Utsugi , T. , Nii , A. and Ogura , T.Effects of human alveolar macrophages on the induction of lymphokine (IL‐2)‐activated killer cells . J. Biol. , 139 , 29 – 34 ( 1987. ). [PubMed] [Google Scholar]
  • 15. ) Sone , S. , Inamura , N. , Nii , A. and Ogura , T.Heterogeneity of human lymphokine (IL‐2)‐activated killer cell precursors and regulation of their LAK induction by blood monocytes . Int. J. Cancer , 42 , 428 – 434 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Figarella , E. F. , Morillo , F. , Blanca , I. and Bicanco , N. E.Failure of cell‐mediated effector mechanism in lung cancer . J. Natl. Cancer Inst. , 73 , 1 – 6 ( 1984. ). [PubMed] [Google Scholar]
  • 17. ) Ginns , L. C. , Goldenheim , P. D. , Miller , L. G. , Burton , R. C. , Gillick , L. , Colvin , R. B. , Goldstein , G. , Kung , P. C. , Hurwitz , C. and Kazemi , H.T‐Lymphocyte subsets in smoking and lung cancer . Am. Rev. Respir. Dis. , 126 , 265 – 269 ( 1982. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Hafjipetrou‐Kourounakis , L. and Tsougranis , A.Diminished lymphocyte responses to phytohemagglutinin in lung cancer . Biochem. Exp. Biol , 16 , 357 – 364 ( 1980. ). [PubMed] [Google Scholar]
  • 19. ) Krant , M. J. , Manskopf , G. , Brandrap , C. S. and Madoff , M. A.Immunologic alterations in bronchogenic cancer . Cancer , 21 , 623 – 631 ( 1968. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Lin , C‐C. , Kuo , Y‐C. , Huang , W‐C. and Lin , C. Y.Natural killer cell activity in lung cancer patients . Chest , 92 , 1022 – 1024 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Masuno , T. , Ikeda , T. , Yokota , S. , Komuta , K. , Ogura , T , and Kishimoto , S.Immunoregulatory T‐lymphocyte functions in patients with small cell lung cancer . Cancer Res. , 46 , 419 – 4199 ( 1986. ). [PubMed] [Google Scholar]
  • 22. ) Nielsen , H. , Bennedsen , J. , Larsen , S. O. , Dombernowsky , P. and Viskum , K.A quantitative and qualitative study of blood monocytes in patients with bronchogenic carcinoma , Cancer Immunol. Immunother. , 13 , 93 – 97 ( 1982. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. ) Sibbit , W. L. , Jr. , Bankhurst , A. D. , Jumonville , A. J. , Saiki , J. H. , Saiers , J. H. and Doberneck , R. C.Defects in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma . Cancer Res. , 44 , 852 – 856 ( 1984. ). [PubMed] [Google Scholar]
  • 24. ) Sone , S. , Utsugi , T. , Tandon , P. , Yanagawa , H. , Okubo , A. and Ogura , T.Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients . Cancer Immunol. Immunother. , 30 , 357 – 362 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. ) McElhaney , J. E. , Beattie , B. L. , Devine , R. , Grynoch , R. , Toth , E. L. and Bleackley , R. C.Age‐related decline in interleukin 2 production in response to influenza vaccine . J. Am. Geriatr. Soc. , 38 , 652 – 658 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Negoro , S. , Kara , H. , Miyata , S. , Saiki , O. , Tanaka , T. , Yoshizaki , K. , Igarashi , T. and Kishimoto , S.Mechanism of age‐related decline in antigen‐specific T cell proliferative response: IL‐2 receptor expression and r‐IL‐2 induced proliferative response of purified Tac positive T cells . Mech. Ageing Dev. , 36 , 223 – 241 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Mountain , C. F. , Carr , D. T. and Anderson , W. A. D.A system for the clinical staging of lung cancer . Am. J. Roentgenol , 120 , 130 – 138 ( 1974. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Lighart , G. J. , Corberand , J. X. , Fournier , C. , Galanaud , P. , Hijmans , W. , Kennes , B. , Muller‐Hermelink , H. K. and Steinmann , G. G.Admission criteria for immunolog‐ical studies in man: the senior protocol . Mech. Ageing Dev. , 28 , 47 – 55 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Kimura , S. , Sone , S. , Takahashi , K. , Uyama , T. , Ogura , T. and Monden , Y.Antitumor potential of pleural cavity macrophages in lung cancer patients without malignant effusion . Br. J. Cancer , 59 , 535 – 539 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. ) Rosenberg , S. A. , Spiess , P. and Lafrenier , R.A new approach to the adoptive immunotherapy of cancer with tumor‐infiltrating lymphocytes . Science , 233 , 1318 – 1321 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 31. ) Pisani , R. J. , Krco , C. J. , Wold , L. E. and McKean , D. JLymphokine‐activated killer (LAK) cell activity in tumor‐infiltrating lymphocytes from non‐small cell lung cancer . Am. J. Clin. Pathol. , 92 , 435 – 446 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Yano , T. , Yasumoto , K. , Togami , M. , Ishida , T. , Kimura , G. , Sugimachi , K. and Nomoto , K.Properties of recom‐binant interleukin 2‐cultured tumor‐infiltrating lymphocytes in human lung cancer . Int. J. Cancer , 43 , 619 – 623 ( 1989. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES